Biohaven Pharmaceutical Holding Company Ltd. BHVN Income Statement

Biohaven pharmaceutical holding company ltd. (BHVN)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16
Product revenue, net
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Cost of goods sold
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Gross profit
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Operating expenses:
Research and development
359,740	344,673	316,612	302,300	155,375	189,951	174,679	162,313	154,280	89,441	87,147	79,196	63,899	55,529	0	0	0
Selling, general and administrative
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
-	134,449	75,587	54,379	-	34,603	30,109	27,106	22,241	18,141	14,979	11,328	8,253	5,109	0	0	0
Total operating expenses
576,328	479,118	392,195	356,675	195,579	224,554	204,788	189,419	176,521	107,582	102,126	90,524	72,152	60,638	0	0	0
Loss from operations
-575,601	-479,118	-392,195	-356,675	-195,579	-224,554	-204,788	-189,419	-176,521	-107,582	-102,126	-90,524	-72,152	-60,638	0	0	0
Other income (expense):
Non-cash interest expense on mandatorily redeemable preferred shares
18,272	12,711	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense
-	-	-	-	-	-	-	-	-	906	1,198	1,052	0	0	0	-	-
Non-cash interest expense on liability related to sale of future royalties
28,192	26,584	24,868	23,193	18,543	11,726	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-	-	-	-	-	1,182	-1,086	1,340	3,969	3,241	5,357	2,929	0	0	0	-	-
Change in fair value of derivative liability
9,656	3,875	0	0	0	-	-	-	-	-512	-552	-423	-227	65	0	0	0
Change in fair value of contingent equity liability
-	-	-	-	-	-	-	-	-	13,082	15,345	0	0	0	-	-	-
Loss from equity method investment
-6,556	-6,076	-5,050	-3,754	-2,980	-2,808	-2,747	-2,688	-2,395	-1,885	-1,376	-813	0	0	0	-	-
Other
-157	-22	-181	-203	-173	-185	0	0	0	-	-	-	-	-2,806	0	0	0
Total other expense, net
-62,833	-49,268	-41,412	-32,368	-21,696	-15,901	-7,834	-4,783	-16,478	-18,602	0	0	0	-	-	-	-
Loss before provision for income taxes
-638,434	-528,386	-433,607	-389,043	-217,275	-240,455	-212,622	-194,202	-192,999	-126,184	-124,840	-110,240	-79,018	-63,444	0	0	0
Provision for income taxes
1,004	419	684	522	489	467	632	526	900	1,006	737	0	0	0	-	-	-
Net loss and comprehensive loss
-639,438	-528,805	0	0	0	-	-	-	-	-127,190	-125,577	-110,922	-79,301	-63,534	0	0	0
Net loss attributable to non-controlling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-143	0	0	0
Accretion of beneficial conversion feature on Series A preferred shares
-	-	-	-	-	-	-	-	-	12,006	0	0	0	-	-	-	-
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.
-	-528,805	-434,291	-389,565	-	-240,922	-213,254	-194,728	-201,905	-139,196	-137,795	-123,090	-83,479	-63,677	0	0	0
Net loss per share - basic and diluted (in dollars per share)
-3.07	-2.85	-2.04	-4.67	-1.41	-1.34	-1.53	-1.01	-2.32	-0.75	-1.19	-1.78	-1.74	-1.96	-2.16	-0.55	-0.25
Weighted average common shares outstanding - basic and diluted (shares)
56,412	52,285	52,077	45,226	44,242	40,938	40,147	38,942	36,793	35,984	35,930	26,038	13,088	13,088	13,050	12,507	11,776